Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sebetralstat for Preprocedural Short-term Prophylaxis in Hereditary Angioedema
NCT07654829Phase 4Recruiting
- Sponsor
- KalVista Pharmaceuticals
- Start
- Aug 2026
- Primary completion
- Nov 2027
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sebetralstat in hereditary angioedema (HAE), sponsored by KalVista Pharmaceuticals. Primary endpoint: Proportion of STPs that did not result in an HAE attack at 24 hours. Started Aug 2026; status: recruiting.
02
Drugs
sebetralstat
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT07654829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07654829.